GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (STU:4AJ0) » Definitions » Capex-to-Operating-Income

Alk-Abello AS (STU:4AJ0) Capex-to-Operating-Income : 0.37 (As of Jun. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Alk-Abello AS Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Alk-Abello AS's Capital Expenditure for the three months ended in Jun. 2024 was €-13.00 Mil. Its Operating Income for the three months ended in Jun. 2024 was €35.37 Mil.

Hence, Alk-Abello AS's Capex-to-Operating-Income for the three months ended in Jun. 2024 was 0.37.


Alk-Abello AS Capex-to-Operating-Income Historical Data

The historical data trend for Alk-Abello AS's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Capex-to-Operating-Income Chart

Alk-Abello AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.48 0.90 0.75 0.57

Alk-Abello AS Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.26 0.53 0.45 0.19 0.37

Competitive Comparison of Alk-Abello AS's Capex-to-Operating-Income

For the Biotechnology subindustry, Alk-Abello AS's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello AS's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's Capex-to-Operating-Income falls into.



Alk-Abello AS Capex-to-Operating-Income Calculation

Alk-Abello AS's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-50.849) / 89.355
=0.57

Alk-Abello AS's Capex-to-Operating-Income for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-12.997) / 35.372
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alk-Abello AS  (STU:4AJ0) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Alk-Abello AS Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello AS Business Description

Traded in Other Exchanges
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.

Alk-Abello AS Headlines

No Headlines